

Supplementary table 1. Baseline characteristic of participants using daily PrEP by the retention (excluding participants who decide to discontinue PrEP due to decreased HIV risk perception)

	All participants (n=491)	Retained in care (n=232)	Lost to follow up (n=259)	P value
Sex assigned at birth				
Male	465 (94.7%)	220 (94.8%)	245 (94.6%)	0.908
Female	26 (5.3%)	12 (5.2%)	14 (5.4%)	
Sexual partners				
No answer	1 (0.2%)	1 (0.4%)	0 (0.0%)	0.295
Men exclusively	419 (85.3%)	202 (87.1%)	217 (83.8%)	
Men and women	71 (14.5%)	29 (12.5%)	42 (16.2%)	
HIV exposure within the past 3 days				
No HIV exposure	488 (99.4%)	231 (99.6%)	257 (99.2%)	0.637
HIV exposure	2 (0.4%)	1 (0.4%)	1 (0.4%)	
No answer	1 (0.2%)	0 (0.0%)	1 (0.4%)	
Frequency of sexual activity				
≤ 2 times per week	169 (34.4%)	107 (46.1%)	62 (23.9%)	<0.001
>2 times per week	264 (53.8%)	105 (45.3%)	159 (61.4%)	
No answer	58 (11.8%)	20 (8.6%)	38 (14.7%)	
Having sex without condom with people who were at risk of HIV within the past 6 months				
No	130 (26.5%)	53 (22.8%)	77 (29.7%)	0.060
Yes	312 (63.5%)	160 (69.0%)	152 (58.7%)	
No answer	49 (10.0%)	19 (8.2%)	30 (11.6%)	
Number of sexual partner within the past 6 months				
1 sexual partner	115 (23.4%)	64 (27.6%)	51 (19.7%)	0.102
At least 2 sexual partners	370 (75.4%)	166 (71.6%)	204 (78.8%)	
No answer	6 (1.2%)	2 (0.9%)	4 (1.5%)	
Having sex for money or gifts within the past 6 months				
No	461 (93.9%)	225 (97.0%)	236 (91.1%)	0.017
Yes	21 (4.3%)	6 (2.6%)	15 (5.8%)	
No answer	9 (1.8%)	1 (0.4%)	8 (3.1%)	
Diagnosis and/or treatment with an STI within the past 6 months				
No	439 (89.4%)	208 (89.7%)	231 (89.2%)	0.006
Yes	39 (7.9%)	23 (9.9%)	16 (6.2%)	
No answer	13 (2.6%)	1 (0.4%)	12 (4.6%)	
Sharing needles with other people within the past 6 months				
No	486 (99.8%)	230 (100.0%)	256 (99.6%)	0.344

Yes	0 (0.0%)	0 (0.0%)	0 (0.0%)	
No answer	1 (0.2%)	0 (0.0%)	1 (0.4%)	
Used PrEP within the past 6 months				
No	451 (92.6%)	199 (86.5%)	252 (98.1%)	<0.0001
Yes	33 (6.8%)	31 (13.5%)	2 (0.8%)	
No answer	3 (0.6%)	0 (0.0%)	3 (1.2%)	
Willingness to pay for PrEP				
< \$4.25/month	100 (20.4%)	44 (19.0%)	56 (21.6%)	0.101
\$4.25-\$14.89/month	302 (61.5%)	138 (59.5%)	164 (63.3%)	
\$14.89-42.55\$/month	67 (13.6%)	41 (17.7%)	26 (10.0%)	
>\$42.55/month	1 (0.2%)	1 (0.4%)	0 (0.0%)	
Don't want/unable to pay for PrEP	21 (4.3%)	8 (3.4%)	13 (5.0%)	

Supplementary table 3. Concerns about potential barriers to access PrEP at baseline

	All	Daily PrEP	ED-PrEP
Anticipated barrier to PrEP	338 (36.5%)	265 (39.4%)	73 (28.9%)
Concern about side effects	9 (1.0%)	9 (1.3%)	0 (0.0%)
Difficult in managing the time for visiting clinic and drug pick up PrEP	8 (0.9%)	5 (0.7%)	3 (1.2%)
Concerned about stigma/community perception	8 (0.9%)	8 (1.2%)	0 (0.0%)
Concerned about family finding out	6 (0.6%)	6 (0.9%)	0 (0.0%)
Concern about cost	6 (0.6%)	6 (0.9%)	0 (0.0%)
Concerned about stigma/community perception	4 (0.4%)	4 (0.6%)	0 (0.0%)
Difficulty in planning sex in advance	3 (0.3%)	1 (0.1%)	2 (0.8%)
Concerned about carrying the pills	2 (0.2%)	2 (0.3%)	0 (0.0%)
Difficulty in taking the pills 2 hours before sex	1 (0.1%)	1 (0.1%)	0 (0.0%)
Difficulty in remembering to take tablet everyday	1 (0.1%)	0 (0.0%)	1 (0.4%)
Drug storage	1 (0.1%)	1 (0.1%)	0 (0.0%)
Difficulty in managing the time for visiting clinic and drug pick up	1 (0.1%)	0 (0.0%)	1 (0.4%)
Concerned on the comorbidity of asthma	1 (0.1%)	0 (0.0%)	1 (0.4%)
Difficulty in transportation of PrEP	0 (0.0%)	0 (0.0%)	0 (0.0%)
Concerned about partner finding out	0 (0.0%)	0 (0.0%)	0 (0.0%)
Difficulty in remembering to take the following doses	0 (0.0%)	0 (0.0%)	0 (0.0%)
Difficulty in accessing STI, hepatitis testing and/or treatment	0 (0.0%)	0 (0.0%)	0 (0.0%)

Supplementary table 3. Challenges reported by daily PrEP users at 3, 6 and 12 months interviews

	3 months N= 373	6 months N=235	12 months N=44
Willing to pay for PrEP per month			

Don't want/unable to pay for PrEP	19 (5.1%)	9 (3.8%)	0 (0.0%)
>\$42.55	1 (0.3%)	1 (0.4%)	0 (0.0%)
\$14.89-42.55\$	45 (12.1%)	36 (15.3%)	21 (47.7%)
\$4.25-\$14.89	240 (64.3%)	152 (64.7%)	22 (50.0%)
< \$4.25	68 (18.2%)	36 (15.3%)	1 (2.3%)
In the past 3 months, do you use daily PrEP or ED PrEP?			
Both daily and ED PrEP	17 (4.6%)	3 (1.3%)	0 (0.0%)
Daily PrEP	296 (79.4%)	190 (80.9%)	36 (81.8%)
Any difficulties in taking PrEP medication in the past 3 months	110 (29.5%)	22 (9.4%)	13 (29.5%)
Forgot to take one or more PrEP doses	37 (9.9%)	9 (3.8%)	5 (11.4%)
Fitting PrEP into daily routine (for daily PrEP users)	7 (1.9%)	1 (0.4%)	1 (2.3%)
Unsure when to take PrEP medications	1 (0.3%)	1 (0.4%)	0 (0.0%)
Didn't know what to do about a missed dose	5 (1.3%)	3 (1.3%)	2 (4.5%)
Concerns about interactions with other medications	11 (2.9%)	5 (2.1%)	7 (15.9%)
Concerns about interactions with alcohol	2 (0.5%)	3 (1.3%)	2 (4.5%)
Concerns about interactions with hormonal therapy	1 (0.3%)	1 (0.4%)	0 (0.0%)
Have you had any difficulties accessing PrEP services?	131 (35.1%)	53 (22.6%)	18 (40.9%)
Difficult in managing the time for visiting clinic and drug pick up	37 (9.9%)	18 (7.7%)	6 (13.6%)
Transportation difficulty	11 (2.9%)	13 (5.5%)	13 (29.5%)
Concerned about partner finding out	5 (1.3%)	5 (2.1%)	1 (2.3%)
Concerned about family finding out	32 (8.6%)	12 (5.1%)	2 (4.5%)
Concerned about stigma/community perception	9 (2.4%)	5 (2.1%)	0 (0.0%)
Difficulty in remembering to take tablet everyday	17 (4.6%)	2 (0.9%)	0 (0.0%)
Carrying the pills with me	13 (3.5%)	7 (3.0%)	5 (11.4%)
Concern about side effects	52 (13.9%)	12 (5.1%)	4 (9.1%)
Concern about cost	9 (2.4%)	1 (0.4%)	0 (0.0%)
Difficulty in accessing STI, Hepatitis testing and/or treatment	5 (1.3%)	3 (1.3%)	1 (2.3%)
Health services closed due to Covid-19	33 (8.8%)	21 (8.9%)	16 (36.4%)

Not able to leave home due to Covid-19 lockdown	34 (9.1%)	27 (11.5%)	15 (34.1%)
Side effects			
Sleepy	1 (0.3%)	0 (0.0%)	0 (0.0%)
Nausea	12 (3.2%)	1 (0.4%)	1 (2.3%)
Muscle pain	1 (0.3%)	0 (0.0%)	0 (0.0%)
Loss of appetite	2 (0.5%)	0 (0.0%)	0 (0.0%)
Headache	3 (0.8%)	3 (1.3%)	2 (4.5%)
Dry lips	5 (1.3%)	2 (0.9%)	1 (2.3%)
Burning	5 (1.3%)	2 (0.9%)	4 (9.1%)
Acne	0 (0.0%)	0 (0.0%)	2 (4.5%)
Hyperpigmentation	0 (0.0%)	0 (0.0%)	0 (0.0%)
Fatigue	7 (1.9%)	6 (2.5%)	1 (2.3%)
Dizziness	7 (1.9%)	0 (0.0%)	0 (0.0%)
Dry skin	0 (0.0%)	0 (0.0%)	1 (2.3%)

Supplementary table 4. Number of participants switching between daily and ED-PrEP during the following up period

	Regimen	Participants preferred a daily PrEP regimen	
During the first 3 months of PrEP use	Daily PrEP	296	80.0%
	ED-PrEP	57	15.4%
	Switching between daily and ED-PrEP	17	4.6%
	Subtotal	370	100.0%
Between 3 months and 6 months of PrEP use	Daily PrEP	190	81.2%
	ED-PrEP	41	17.5%

	Switching between daily and ED-PrEP	3	1.3%
	Subtotal	234	100.0%
Between 9 and 12 months of PrEP use	Daily PrEP	36	83.7%
	ED-PrEP	7	16.3%
	Switching between daily and ED-PrEP	0	0.0%
	Subtotal	43	100.0%